Core Concepts
MRI-guided biopsies for prostate cancer are cost-effective.
Abstract
TOPLINE:
MRI-based biopsies for prostate cancer are cost-effective.
METHODOLOGY:
Simulation of 65-year-old men at risk for cancer.
Compared costs and benefits of ultrasound vs. MRI-guided biopsies.
Cost-effectiveness measured over a decade.
MRI approach cost-effective for PSA levels 2.5-4.0 ng/mL, 4.1-10.0 ng/mL, and >10.0 ng/mL.
TAKEAWAY:
MRI plus MRI-guided biopsy cost-effective for three PSA levels.
Cost difference between MRI and ultrasound varied based on PSA levels.
IN PRACTICE:
Growing consensus on cost-effectiveness of MRI and MRI-guided biopsy.
SOURCE:
Study led by Ali Jalali, PhD from Weill Cornell Medicine.
LIMITATIONS:
Study based on hypothetical simulation, not real-world data.
Assumes constant PSA levels over time.
DISCLOSURES:
Authors have affiliations with Siemens Healthineers and Promaxo Inc.
Stats
Cost-effectiveness defined as less than $100,000 for each life-year gain using MRI.
MRI-based approach cost $6000 more than ultrasound for life-year gain at PSA level >10.0 ng/mL.
Difference between MRI and ultrasound at PSA level <2.5 ng/mL was $187,000.
Quotes
"A growing consensus that the use of MRI and potential MRI-guided biopsy is cost-effective."